Digma aims to harness the power of the small intestine to empower patients and physicians with safe, simple and effective new therapies for type 2 diabetes that dramatically improve their quality of life and long-term health outcomes.
We are developing a minimally invasive therapy, Endoscopic Glycemic Management (EGM), that aims to restore the body’s natural ability to control blood glucose levels. The treatment targets the duodenal submucosa which is central to nutrient sensing and metabolic signaling .
Our product is compatible with standard gastrointestinal endoscopes and the EGM procedure is being developed so that it can be performed in a standard GI endoscopy suite without requiring additional imaging equipment. Our goal is to provide patients with durable improvement in glycemic control with minimal side effects and without requiring additional daily medical therapy.
The EGM procedure is currently being evaluated in clinical studies. To learn more about our clinical program, please contact us.
We are developing a minimally invasive therapy, Endoscopic Glycemic Management (EGM), that aims to restore the body’s natural ability to control blood glucose levels. The treatment targets the duodenal submucosa which is central to nutrient sensing and metabolic signaling .
Our product is compatible with standard gastrointestinal endoscopes and the EGM procedure is being developed so that it can be performed in a standard GI endoscopy suite without requiring additional imaging equipment. Our goal is to provide patients with durable improvement in glycemic control with minimal side effects and without requiring additional daily medical therapy.
The EGM procedure is currently being evaluated in clinical studies. To learn more about our clinical program, please contact us.
Location: Israel, Tel Aviv, Hertsliyah
Employees: 11-50
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Arkin Hold... | arkinholdi... |
Mentions in press and media 10
| Date | Title | Description |
| 27.12.2022 | Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners | /EIN News/ -- SANTA CLARA, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced to... |
| 27.12.2022 | Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners | - |
| 22.03.2021 | Accelmed closes $400M fund, invests in medication adherence company | “Over the past decade, we have served as a trusted value-add partner to health-tech companies and management teams who are looking to take their businesses to the next level but lack the resources and expertise to execute on these aspiratio... |
| 18.03.2021 | Accelmed closes $400M healthtech fund | Accelmed Partners has closed its second flagship fund on a hard cap of $400 million, passing its original $300 million target. The Florida-based PE firm focuses on backing commercial-stage healthtech companies in the lower middle market. Ac... |
| 17.03.2021 | Accelmed Partners Raises $400 Million to Invest in Commercial Stage HealthTech | AVENTURA, Fla.--(BUSINESS WIRE)--Mar 17, 2021-- Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and investing in U.S. commercial stage, lower middle market HealthTech companies, today announced the successful clos... |
| 17.03.2021 | Accelmed closes $400M fund amid high healthtech demand | The private equity firm Accelmed Partners has closed its second fund, with plans to invest $400 million in the development of commercial-stage health technology companies. The oversubscribed fund hit its hard cap after passing its original ... |
| 17.03.2021 | Healthtech demand has ‘never been greater’ says Accelmed, as firm closes second PE fund on $400m hard cap | Accelmed Partners has hit a $400m hard cap final close for its second fundraise, saying demand for technology-enabled he |
| 17.03.2021 | Accelmed closes $400M fund amid high healthtech demand | The private equity firm Accelmed Partners has closed its second fund, with plans to invest $400 million in the development of commercial-stage health technology companies. Accelmed Fund II will mainly focus on producers of medical devices, ... |
| 02.04.2018 | STRATA Skin Sciences Announces $17M Equity Financing Led by Accelmed Growth Partners | HORSHAM, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ:SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for t... |
| - | Accelmed closes $400M fund, invests in medication adherence company | Private equity firm Accelmed Partners recently closed a $400 million oversubscribed second fund. The Florida-based firm invests in health-tech companies with revenues between $20 million and $70 million. Accelmed’s strategy involves working... |